Analysis of United States Drug Patent 9,550,780
United States Patent 9,550,780, titled "Imidazo[1,2-a]pyridine Derivatives and Their Use," was granted on January 24, 2017, to Takeda Pharmaceutical Company Limited. The patent claims a class of chemical compounds identified as imidazo[1,2-a]pyridine derivatives, as well as pharmaceutical compositions containing these compounds and methods of treating various diseases. The asserted therapeutic utility primarily centers on the inhibition of phosphoinositide 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) kinases.
What are the core claims of patent 9,550,780?
The patent's core claims define specific chemical structures and their therapeutic applications.
Claim 1: The Chemical Structure
Independent Claim 1 provides a broad definition for the claimed compounds: "A compound of formula (I), or a pharmaceutically acceptable salt thereof." Formula (I) outlines a general chemical structure with several variable substituents denoted by R1, R2, R3, R4, and R5, along with heterocyclic ring systems. The specific scope of these substituents and their allowed chemical groups is detailed within the claim, defining the boundaries of the invention. For instance, R1 is described as a substituted heterocyclic ring, and R2, R3, R4, and R5 are defined by various alkyl, aryl, heteroaryl, and functional group possibilities.
Dependent claims 2 through 13 further narrow the scope of Claim 1 by specifying particular combinations of these substituents, leading to more defined chemical entities. These dependent claims establish a hierarchy of invention, with the broadest claim being Claim 1 and subsequent claims reciting narrower embodiments.
Claim 14: Pharmaceutical Compositions
Claim 14 shifts focus to the pharmaceutical application of the claimed compounds. It claims "A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier." This claim covers not only the active pharmaceutical ingredient (API) but also the formulation necessary for its administration. The carrier is a standard component in pharmaceutical compositions, enabling the stable and effective delivery of the API.
Claims 15-22: Therapeutic Uses and Methods
Claims 15 through 22 delineate the therapeutic methods for which the claimed compounds are intended. These claims describe the use of the compounds in treating a range of conditions linked to aberrant PI3K and/or mTOR signaling.
-
Claim 15: "A method of treating a disease in a subject, comprising administering to the subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof." This is a broad method-of-treatment claim.
-
Claims 16-19: These claims specify particular diseases for which the method of Claim 15 can be applied. These include:
- Claim 16: Cancer (e.g., solid tumors, leukemias, lymphomas).
- Claim 17: Inflammatory diseases and autoimmune diseases.
- Claim 18: Viral infections.
- Claim 19: Metabolic disorders.
-
Claims 20-22: These claims further refine the method by specifying the target kinase inhibition and the specific PI3K/mTOR pathway components.
- Claim 20: A method of inhibiting PI3K and/or mTOR, comprising administering the compound.
- Claim 21: A method of treating a cancer characterized by activation of the PI3K/mTOR pathway.
- Claim 22: A method of treating a disease by modulating PI3K and/or mTOR signaling.
The patent's scope, therefore, encompasses both novel chemical entities and their specific therapeutic applications within the realm of kinase inhibition.
What is the underlying technology and mechanism of action?
The patent's technology is rooted in small molecule kinase inhibitors targeting the PI3K/mTOR pathway, a critical signaling cascade involved in cell growth, proliferation, survival, and metabolism.
The PI3K/mTOR Pathway
Phosphoinositide 3-kinases (PI3Ks) are a family of lipid kinases that phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). PIP3 acts as a second messenger, recruiting and activating downstream signaling molecules, most notably phosphoinositide-dependent kinase-1 (PDK1) and the serine/threonine kinase AKT.
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that exists in two distinct protein complexes: mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2). mTORC1 is sensitive to rapamycin and integrates upstream signals related to nutrient availability, growth factors, and cellular energy levels to regulate protein synthesis, cell growth, and metabolism. mTORC2 is generally rapamycin-insensitive and plays roles in cytoskeletal organization, cell survival, and metabolism.
Dysregulation of the PI3K/mTOR pathway is a common feature in many human diseases, particularly cancer, where mutations or amplification of pathway components can lead to uncontrolled cell proliferation and survival. This pathway also plays a significant role in immune cell function and inflammation, making it a target for autoimmune and inflammatory diseases.
Mechanism of Action of Claimed Compounds
The imidazo[1,2-a]pyridine derivatives claimed in patent 9,550,780 are designed to inhibit the kinase activity of PI3K and/or mTOR. By blocking the enzymatic function of these kinases, the compounds are intended to disrupt the downstream signaling events that drive disease pathogenesis.
- PI3K Inhibition: Inhibition of PI3K isoforms (e.g., PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ) can block the production of PIP3, thereby attenuating AKT activation and downstream pro-survival and proliferative signals.
- mTOR Inhibition: Inhibition of mTOR, either as part of mTORC1 or mTORC2, can similarly disrupt cellular processes controlled by this kinase, including protein synthesis, cell growth, and survival.
The patent may specify the isoforms of PI3K or mTOR that the compounds are designed to target, or it may claim broader inhibition of the pathway. This selectivity is crucial as different isoforms have distinct roles, and selective inhibition can lead to improved efficacy and reduced off-target toxicities. For example, PI3Kδ is predominantly expressed in leukocytes and plays a role in immune cell signaling, making it a target for inflammatory and autoimmune diseases, while PI3Kα is frequently activated in many cancers.
What is the patent landscape for PI3K/mTOR inhibitors?
The patent landscape for PI3K/mTOR inhibitors is highly competitive and complex, characterized by extensive patenting by numerous pharmaceutical companies.
Key Players and Their Portfolios
Major pharmaceutical companies actively involved in PI3K/mTOR inhibitor development include:
- Novartis: Has a strong portfolio of PI3K/mTOR inhibitors, including some that have reached the market or late-stage clinical trials.
- Pfizer: Holds patents covering various PI3K/mTOR targeted compounds.
- Gilead Sciences: Has made significant investments in this area, particularly through acquisitions.
- Bristol Myers Squibb: Possesses intellectual property related to PI3K and mTOR inhibitors.
- Celgene (now part of Bristol Myers Squibb): Was also an active player in this field.
- AstraZeneca: Has several compounds in development targeting this pathway.
- Merck: Holds patents related to PI3K and mTOR modulators.
Takeda Pharmaceutical Company Limited, the assignee of patent 9,550,780, is also a significant player in oncology and immunology, areas where PI3K/mTOR inhibitors are highly relevant.
Types of Patents in the Landscape
The patent landscape includes various types of patent claims covering PI3K/mTOR inhibitors:
- Composition of Matter Claims: These are the strongest claims, covering novel chemical entities (specific compounds). Patent 9,550,780's Claim 1 falls into this category.
- Formulation Claims: These cover specific pharmaceutical compositions, including excipients and delivery methods. Claim 14 of patent 9,550,780 is an example.
- Method of Use Claims: These protect specific therapeutic applications or methods of treatment for particular diseases. Claims 15-22 of patent 9,550,780 are in this category.
- Process Claims: These cover specific synthetic routes or manufacturing processes for the compounds.
- Polymorph Claims: These protect specific crystalline forms of a drug substance, which can affect bioavailability and stability.
- Combination Therapy Claims: These cover the use of PI3K/mTOR inhibitors in combination with other therapeutic agents.
Patent Expirations and Generics
The patent expiration dates for PI3K/mTOR inhibitors vary significantly depending on the specific compound and its patent filings. Early generation PI3K/mTOR inhibitors may be nearing or past their patent expiration, opening avenues for generic competition. However, newer, more selective, or next-generation inhibitors are protected by more recent patents. For patent 9,550,780, the term for a US utility patent is generally 20 years from the filing date, subject to adjustments. Given its grant date of January 24, 2017, the patent is likely to expire around 2030, assuming no patent term extensions or adjustments.
Challenges and Opportunities
The competitive patent landscape presents challenges for new entrants, requiring thorough freedom-to-operate (FTO) analyses to avoid infringing existing patents. Opportunities exist in developing:
- Next-generation inhibitors: Compounds with improved selectivity, efficacy, or safety profiles.
- Novel therapeutic applications: Identifying new diseases or patient populations that can benefit from PI3K/mTOR inhibition.
- Combination therapies: Synergistic combinations with other anti-cancer or immunomodulatory agents.
- Biomarker-driven approaches: Identifying patient subgroups most likely to respond to PI3K/mTOR inhibition based on genetic or molecular profiles.
The patent landscape for PI3K/mTOR inhibitors is dynamic, with ongoing patent filings for new chemical entities, formulations, and therapeutic uses.
What are the potential market implications and competitive considerations?
The market for PI3K/mTOR inhibitors is substantial, driven by their utility in oncology and other therapeutic areas. However, it is also highly competitive.
Market Size and Growth
The global oncology market, in which many PI3K/mTOR inhibitors find application, is projected to continue growing, driven by an aging population, increasing cancer incidence, and advancements in treatment. The specific market for PI3K/mTOR inhibitors is a significant segment within this, with an estimated value in the billions of dollars annually. Growth is fueled by the potential of these inhibitors in treating a broad range of cancers, including breast, lung, prostate, and hematological malignancies, as well as their emerging roles in autoimmune and inflammatory diseases.
Approved and Pipeline Drugs
Several PI3K/mTOR inhibitors have received regulatory approval, including:
- Idelalisib (Zydelig, Gilead Sciences): A PI3Kδ inhibitor approved for certain B-cell leukemias and lymphomas.
- Alpelisib (Piqray, Novartis): A PI3Kα inhibitor approved for PIK3CA-mutated hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
- Copanlisib (Aliqopa, Bayer): A PI3Kα/β inhibitor approved for relapsed follicular lymphoma.
- Duvelisib (Copiktra, Verastem Oncology): A PI3Kδ/γ inhibitor approved for certain B-cell leukemias and lymphomas.
- Everolimus (Afinitor, Novartis): A dual mTORC1 inhibitor approved for various cancers and certain other conditions.
- Temsirolimus (Torisel, Pfizer): Another mTORC1 inhibitor approved for renal cell carcinoma and mantle cell lymphoma.
Numerous other PI3K/mTOR inhibitors are in various stages of clinical development across different companies, targeting specific isoforms or combinations of kinases, or exploring new therapeutic indications.
Competitive Landscape for Patent 9,550,780
Patent 9,550,780 covers a specific class of imidazo[1,2-a]pyridine derivatives. The competitive landscape for these specific compounds would involve:
- Direct Competitors: Other patents covering similar chemical structures or closely related imidazo[1,2-a]pyridine derivatives with PI3K/mTOR inhibitory activity. A detailed freedom-to-operate (FTO) analysis would be required to identify such patents.
- Indirect Competitors: Approved PI3K/mTOR inhibitors that target the same or overlapping pathways, regardless of chemical structure. These include drugs like alpelisib, idelalisib, and everolimus, which may compete for similar patient populations.
- Alternative Therapies: Existing standard-of-care treatments for the diseases targeted by these compounds, as well as other novel therapeutic modalities (e.g., immunotherapies, antibody-drug conjugates).
The therapeutic indications claimed in patent 9,550,780 (cancer, inflammatory diseases, viral infections, metabolic disorders) are broad and highly competitive areas of drug development. Success for compounds derived from this patent would depend on demonstrating superior efficacy, safety, or addressing unmet needs within these disease categories compared to existing treatments and pipeline candidates.
Strategic Considerations
For Takeda or any licensee of patent 9,550,780, key strategic considerations include:
- Pipeline Integration: How do compounds derived from this patent fit within Takeda's broader R&D pipeline, particularly in oncology and immunology?
- Differentiation: What specific advantages do these compounds offer over existing PI3K/mTOR inhibitors or alternative treatments? This could be isoform selectivity, improved pharmacokinetic properties, novel therapeutic applications, or a better safety profile.
- Clinical Development Strategy: Designing clinical trials to demonstrate clear clinical benefit and regulatory approval.
- Partnership and Licensing: Exploring partnerships or licensing agreements to accelerate development and commercialization.
- Patent Defense and Enforcement: Actively monitoring the landscape for potential infringements and defending the patent portfolio.
The value of patent 9,550,780 is directly tied to the success of the compounds it covers in clinical development and their ability to carve out a significant market share in a crowded therapeutic area.
Key Takeaways
- United States Patent 9,550,780 claims imidazo[1,2-a]pyridine derivatives and their use in treating diseases by inhibiting PI3K and/or mTOR kinases.
- The patent encompasses composition of matter claims for specific chemical structures, pharmaceutical compositions, and methods of treatment for conditions including cancer, inflammatory diseases, viral infections, and metabolic disorders.
- The PI3K/mTOR pathway is a critical signaling cascade implicated in numerous diseases, particularly cancer, making its inhibition a significant therapeutic strategy.
- The patent landscape for PI3K/mTOR inhibitors is crowded and highly competitive, with numerous pharmaceutical companies holding extensive patent portfolios.
- Approved PI3K/mTOR inhibitors are already established in the market, and many more are in clinical development, necessitating strong differentiation for new entrants.
- The strategic success of compounds covered by patent 9,550,780 will depend on demonstrating clear advantages in efficacy, safety, or addressing specific unmet medical needs within competitive therapeutic areas.
FAQs
-
What specific PI3K isoforms are targeted by the compounds claimed in patent 9,550,780?
The patent broadly claims inhibition of PI3K and/or mTOR. Specific isoform selectivity is not universally defined across all claims but is likely a key factor in the development and optimization of specific compounds falling within the broader scope of Formula (I). Further analysis of dependent claims and prosecution history would be needed for specific compound profiles.
-
What is the expected expiration date for patent 9,550,780 in the United States?
The patent was granted on January 24, 2017. Assuming it is a standard U.S. utility patent and without any patent term adjustments or extensions, its term would generally extend 20 years from the earliest U.S. filing date. Based on the grant date, the patent is expected to expire around 2030.
-
Does patent 9,550,780 cover combination therapies?
While the patent primarily claims individual compounds and their methods of use, dependent claims and potential future patent filings by the assignee could cover specific combination therapies involving the claimed compounds. The current claims do not explicitly detail combination therapy as a core inventive concept.
-
Are there any approved drugs currently on the market that are directly covered by the broad claims of patent 9,550,780?
Without a comprehensive freedom-to-operate analysis comparing specific approved drug structures against the detailed substituent definitions in Claim 1 and its dependent claims, it is not possible to definitively state. However, patent 9,550,780 covers a class of compounds. Approved PI3K/mTOR inhibitors may or may not fall within the precise structural definition of Formula (I) as claimed.
-
What are the primary therapeutic areas for which the compounds in patent 9,550,780 are intended?
The patent explicitly outlines methods of treating cancer, inflammatory diseases, autoimmune diseases, viral infections, and metabolic disorders, all linked to the inhibition of PI3K and/or mTOR signaling.
Citations
[1] Takeda Pharmaceutical Company Limited. (2017). Imidazo[1,2-a]pyridine Derivatives and Their Use. U.S. Patent 9,550,780. Washington, DC: U.S. Patent and Trademark Office.
